MX2022006663A - Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este. - Google Patents
Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este.Info
- Publication number
- MX2022006663A MX2022006663A MX2022006663A MX2022006663A MX2022006663A MX 2022006663 A MX2022006663 A MX 2022006663A MX 2022006663 A MX2022006663 A MX 2022006663A MX 2022006663 A MX2022006663 A MX 2022006663A MX 2022006663 A MX2022006663 A MX 2022006663A
- Authority
- MX
- Mexico
- Prior art keywords
- oxygen
- containing heterocyclic
- heterocyclic compound
- preparation
- application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se divulga un compuesto heterocíclico que contiene oxígeno, un método de preparación de este y el uso de este. La presente divulgación proporciona un compuesto heterocíclico que contiene oxígeno representado por la fórmula I, una sal farmacéuticamente aceptable de este, un estereoisómero de este, un tautómero de este o un compuesto isotópico de este. Cabe esperar que el compuesto heterocíclico que contiene oxígeno pueda tratar y/o prevenir diversas enfermedades mediadas por Ras. (ver Fórmula).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911212840 | 2019-12-02 | ||
CN202010368798 | 2020-04-29 | ||
CN202011077052.0A CN112979664B (zh) | 2019-12-02 | 2020-10-10 | 一种含氧杂环化合物、其制备方法及应用 |
PCT/CN2020/122335 WO2021109737A1 (zh) | 2019-12-02 | 2020-10-21 | 一种含氧杂环化合物、其制备方法及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022006663A true MX2022006663A (es) | 2022-07-05 |
Family
ID=76221416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022006663A MX2022006663A (es) | 2019-12-02 | 2020-10-21 | Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220315598A1 (es) |
EP (1) | EP4015520A4 (es) |
JP (1) | JP7480298B2 (es) |
KR (1) | KR20220136349A (es) |
AU (1) | AU2020395397A1 (es) |
BR (1) | BR112022010254A2 (es) |
CA (1) | CA3163218A1 (es) |
MX (1) | MX2022006663A (es) |
WO (1) | WO2021109737A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
AU2020337938A1 (en) | 2019-08-29 | 2022-03-17 | Array Biopharma Inc. | KRas G12D inhibitors |
AU2020356455A1 (en) | 2019-09-24 | 2022-04-14 | Mirati Therapeutics, Inc. | Combination therapies |
CN114867726B (zh) | 2019-10-28 | 2023-11-28 | 默沙东有限责任公司 | Kras g12c突变体的小分子抑制剂 |
CA3161278A1 (en) | 2019-12-20 | 2021-06-24 | Matthew Arnold Marx | Sos1 inhibitors |
KR20220152295A (ko) | 2020-03-12 | 2022-11-15 | 디3 바이오(우씨) 컴퍼니 리미티드 | 피리미도헤테로사이클릭 화합물 및 이의 응용 |
US20220112204A1 (en) * | 2020-10-14 | 2022-04-14 | Accutar Biotechnology Inc. | Substituted dihydropyranopyrimidine compounds as kras inhibitors |
WO2022187527A1 (en) * | 2021-03-05 | 2022-09-09 | Nikang Therapeutics, Inc | Quinazoline nitrile derivatives as kras inhibitors |
CN115385923A (zh) * | 2021-05-24 | 2022-11-25 | 上海璎黎药业有限公司 | 一种含氧杂环化合物的晶型、其制备方法及应用 |
WO2023008462A1 (ja) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2023205074A1 (en) * | 2022-04-18 | 2023-10-26 | Mirati Therapeutics, Inc. | Processes and intermediates for synthesis of adagrasib |
WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010064705A1 (ja) * | 2008-12-05 | 2010-06-10 | 大日本住友製薬株式会社 | H4受容体アンタゴニスト作用を有する新規7位置換ジヒドロピラノピリミジン誘導体 |
US20100331305A1 (en) * | 2009-06-24 | 2010-12-30 | Genentech, Inc. | Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use |
CN104903312B (zh) * | 2013-10-07 | 2019-01-29 | 卡德门企业有限公司 | Rho激酶抑制剂 |
CA2981530A1 (en) * | 2015-04-10 | 2016-10-13 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
EA201890153A1 (ru) * | 2015-06-26 | 2018-06-29 | КАДМОН КОРПОРЕЙШН, ЭлЭлСи | Ингибиторы поглощения глюкозы |
KR101777475B1 (ko) * | 2015-12-08 | 2017-09-11 | 에스티팜 주식회사 | 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도 |
CA3024523A1 (en) * | 2016-05-18 | 2017-11-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
JP2020521742A (ja) * | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | Krasの共有結合性阻害剤 |
UA125802C2 (uk) * | 2017-11-15 | 2022-06-08 | Міраті Терапьютікс, Інк. | Інгібітори kras g12c |
TW201942115A (zh) * | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
TW201942116A (zh) | 2018-02-09 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌劑之四氫喹唑啉衍生物 |
CN112218859A (zh) * | 2018-04-04 | 2021-01-12 | 阿尔维纳斯运营股份有限公司 | 蛋白水解调节剂及相关使用方法 |
WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
KR20220152295A (ko) * | 2020-03-12 | 2022-11-15 | 디3 바이오(우씨) 컴퍼니 리미티드 | 피리미도헤테로사이클릭 화합물 및 이의 응용 |
-
2020
- 2020-10-21 EP EP20895574.0A patent/EP4015520A4/en active Pending
- 2020-10-21 AU AU2020395397A patent/AU2020395397A1/en active Pending
- 2020-10-21 KR KR1020227022934A patent/KR20220136349A/ko unknown
- 2020-10-21 MX MX2022006663A patent/MX2022006663A/es unknown
- 2020-10-21 US US17/767,046 patent/US20220315598A1/en active Pending
- 2020-10-21 JP JP2022532809A patent/JP7480298B2/ja active Active
- 2020-10-21 BR BR112022010254A patent/BR112022010254A2/pt unknown
- 2020-10-21 CA CA3163218A patent/CA3163218A1/en active Pending
- 2020-10-21 WO PCT/CN2020/122335 patent/WO2021109737A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP7480298B2 (ja) | 2024-05-09 |
US20220315598A1 (en) | 2022-10-06 |
EP4015520A1 (en) | 2022-06-22 |
CA3163218A1 (en) | 2021-06-10 |
AU2020395397A1 (en) | 2022-06-09 |
KR20220136349A (ko) | 2022-10-07 |
WO2021109737A1 (zh) | 2021-06-10 |
JP2023504178A (ja) | 2023-02-01 |
EP4015520A4 (en) | 2023-08-23 |
BR112022010254A2 (pt) | 2022-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022006663A (es) | Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este. | |
PH12020551315A1 (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
GEP20237568B (en) | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
PH12019501688A1 (en) | Pyridine derivative as ask1 inhibitor and preparation method and use thereof | |
MX2022005610A (es) | Pirimidina-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos. | |
EA201890318A1 (ru) | СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ | |
CA2983481A1 (en) | Janus kinase inhibitor | |
WO2017132432A8 (en) | Benzimidazole derivatives as modulators of ror-gamma | |
MX2019003143A (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
MY194468A (en) | Oxy-fluoropiperidine derivatives as kinase inhhiitor | |
PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
EP4342473A3 (en) | Compounds useful in hiv therapy | |
PH12019501955A1 (en) | Tri-cycle compound and applications thereof | |
MY194106A (en) | Dihydroindolizinone derivative | |
MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
MX2019006612A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta). | |
MX2021007247A (es) | Derivados de rapamicina. | |
PH12019550154A1 (en) | Azetidine derivative | |
MX2021012105A (es) | Compuestos de pirrol. | |
ZA202200511B (en) | Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis | |
MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
MX2019002901A (es) | Tratamiento de esclerosis multiple con chs-131. | |
MX2022000729A (es) | Terapia de combinacion para el tratamiento del cancer. | |
WO2019153007A3 (en) | Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same | |
WO2019126695A3 (en) | Methods and pharmaceutical compositions for treating candida auris in blood |